Tokyo, Nov. 20 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059825) titled 'A single-center prospective observational study on the efficacy of stereotactic body radiotherapy for painful spinal bone metastases' on Nov. 19.
Study Type:
Observational
Primary Sponsor:
Institute - National Cancer Center
Condition:
Condition - Painful spinal bone metastases from malignant tumors
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - To evaluate the pane response and treatment-related toxicity of stereotactic body radiotherapy for painful spinal metastatic lesions from malignant tumors
Basic objectives2 - Safety,Efficacy
Eligibility:
Age-lower limit - 20
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - 1) Patients aged 20 years or older at the time of informed consent
2) Patients with an identified primary tumor and a pathological diagnosis of malignancy
3) Patients with painful spinal bone metastases scheduled to undergo stereotactic body radiotherapy
4) Patients whose pain score for the target metastatic lesion is 2 or higher
Key exclusion criteria - Stereotactic body radiotherapy cannot be performed under the current national health insurance system
Target Size - 60
Recruitment Status:
Recruitment status - Open public recruiting
Date of protocol fixation - 2024 Year 01 Month 12 Day
Date of IRB - 2024 Year 01 Month 12 Day
Anticipated trial start date - 2024 Year 01 Month 12 Day
Last follow-up date - 2027 Year 12 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068413
Disclaimer: Curated by HT Syndication.
